1
|
Affiliation(s)
- Y Tomoda
- Department of General Medicine, Saiseikai Fukuoka General Hospital, Tenjin, Chuo-ku, Fukuoka shi, Fukuoka, Japan
| | - S Kagawa
- Department of General Medicine, Saiseikai Fukuoka General Hospital, Tenjin, Chuo-ku, Fukuoka shi, Fukuoka, Japan
| | - S Kurata
- Department of General Medicine, Saiseikai Fukuoka General Hospital, Tenjin, Chuo-ku, Fukuoka shi, Fukuoka, Japan
| | - K Tanaka
- Department of General Medicine, Saiseikai Fukuoka General Hospital, Tenjin, Chuo-ku, Fukuoka shi, Fukuoka, Japan
| |
Collapse
|
2
|
Affiliation(s)
- Y Tomoda
- Department of General Medicine, Saiseikai Fukuoka General Hospital, 1-3-46, Tenjin, Chuo-ku, Fukuoka-shi, Fukuoka 810-0001, Japan
| | - K Ichida
- Department of General Medicine, Saiseikai Fukuoka General Hospital, 1-3-46, Tenjin, Chuo-ku, Fukuoka-shi, Fukuoka 810-0001, Japan
| | - S Kagawa
- Department of General Medicine, Saiseikai Fukuoka General Hospital, 1-3-46, Tenjin, Chuo-ku, Fukuoka-shi, Fukuoka 810-0001, Japan
| | - S Kurata
- Department of General Medicine, Saiseikai Fukuoka General Hospital, 1-3-46, Tenjin, Chuo-ku, Fukuoka-shi, Fukuoka 810-0001, Japan
| | - K Tanaka
- Department of General Medicine, Saiseikai Fukuoka General Hospital, 1-3-46, Tenjin, Chuo-ku, Fukuoka-shi, Fukuoka 810-0001, Japan
| |
Collapse
|
3
|
Shimeno K, Akamatsu K, Kagawa S, Matsushita T, Matsuo M, Yoshiyama T, Matsumura Y, Matsumoto R, Abe Y, Kamimori K, Naruko T. P1507Utility of right ventriculography for anchoring a pacing lead to the right ventricular septum. Europace 2017. [DOI: 10.1093/ehjci/eux158.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Yoshiyama T, Simeno K, Akamatsu K, Kagawa S, Matsushita T, Matsuo M, Matsumoto R, Matsumura Y, Abe Y, Kamimori K, Naruko T. P1696Utility of the plasma human atrial natriuretic peptide for predicting the left atrial reverse remodeling after the catheter ablation in patients with atrial fibrillation. Europace 2017. [DOI: 10.1093/ehjci/eux161.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Matsuo M, Shimeno K, Akamatsu K, Kagawa S, Matsushita T, Yoshiyama T, Matsumoto R, Matsumura Y, Abe Y, Kamimori K, Naruko T. P1509Utility of the combination of simple electrocardiographic parameters for identifying the mid-septal pacing. Europace 2017. [DOI: 10.1093/ehjci/eux158.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Yamauchi H, Kagawa S, Kishibe Y, Takahashi M, Higashi T. Progressive Cortical Neuronal Damage and Extracranial-Intracranial Bypass Surgery in Patients with Misery Perfusion. AJNR Am J Neuroradiol 2017; 38:935-941. [PMID: 28255031 DOI: 10.3174/ajnr.a5110] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Accepted: 12/17/2016] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Misery perfusion may cause selective neuronal damage in atherosclerotic ICA or MCA disease. Bypass surgery can improve misery perfusion and may prevent neuronal damage. On the other hand, surgery conveys a risk for neuronal damage. The purpose of this retrospective study was to determine whether progression of cortical neuronal damage in surgically treated patients with misery perfusion is larger than that in surgically treated patients without misery perfusion or medically treated patients with misery perfusion. MATERIALS AND METHODS We evaluated the distribution of benzodiazepine receptors twice by using PET and 11C-labeled flumazenil in 18 surgically treated patients with atherosclerotic ICA or MCA disease (9 with misery perfusion and 9 without) and no perioperative stroke before and after bypass surgery; in 8 medically treated patients with misery perfusion and no intervening ischemic event; and in 7 healthy controls. We quantified abnormal decreases in the benzodiazepine receptors of the cerebral cortex within the MCA distribution and compared changes in the benzodiazepine receptor index among the 3 groups. RESULTS The change in the benzodiazepine receptor index in surgically treated patients with misery perfusion (27.5 ± 15.6) during 7 ± 5 months was significantly larger than that in surgically treated patients without misery perfusion (-5.2 ± 9.4) during 6 ± 4 months (P < .001) and in medically treated patients with misery perfusion (3.2 ± 15.4) during 16 ± 6 months (P < .01). CONCLUSIONS Progression of cortical neuronal damage in surgically treated patients with misery perfusion and no perioperative stroke may occur and may be larger than that in medically treated patients with misery perfusion and no intervening ischemic event.
Collapse
Affiliation(s)
- H Yamauchi
- From the Division of PET Imaging (H.Y., S.K., Y.K., M.T., T.H.), Shiga Medical Center Research Institute, Moriyama, Japan
| | - S Kagawa
- From the Division of PET Imaging (H.Y., S.K., Y.K., M.T., T.H.), Shiga Medical Center Research Institute, Moriyama, Japan
| | - Y Kishibe
- From the Division of PET Imaging (H.Y., S.K., Y.K., M.T., T.H.), Shiga Medical Center Research Institute, Moriyama, Japan
| | - M Takahashi
- From the Division of PET Imaging (H.Y., S.K., Y.K., M.T., T.H.), Shiga Medical Center Research Institute, Moriyama, Japan
| | - T Higashi
- From the Division of PET Imaging (H.Y., S.K., Y.K., M.T., T.H.), Shiga Medical Center Research Institute, Moriyama, Japan.,National Institute of Radiological Sciences (T.H.), National Institutes of Quantum and Radiological Science and Technology, Chiba, Japan
| |
Collapse
|
7
|
Yano S, Takehara K, Kishimoto H, Tazawa H, Urata Y, Kagawa S, Bouvet M, Fujiwara T, Hoffman RM. OBP-401-GFP telomerase-dependent adenovirus illuminates and kills high-metastatic more effectively than low-metastatic triple-negative breast cancer in vitro. Cancer Gene Ther 2017; 24:45-47. [PMID: 28106046 DOI: 10.1038/cgt.2016.67] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 10/17/2016] [Accepted: 10/18/2016] [Indexed: 11/09/2022]
Abstract
We previously described the development of a highly-invasive, triple-negative breast cancer (TNBC) variant using serial orthotopic implantation of MDA-MB-231 human breast cancer in nude mice. The isolated variant is highly invasive in the mammary gland and metastasized to lymph nodes in 10 of 12 mice compared with 2 of 12 of the parental cell line. OBP-401 is a telomerase-dependent cancer-specific, green fluorescent protein (GFP)-expressing adenovirus. OBP-401 was used to infect parental MDA-MB-231P cells and high-metastatic MDA-MB-231H and MDA-MB-231HLN isolated from a lymph node metastasis and MDA-MB-231HLM isolated from a lung metastasis. Time-course imaging showed that OBP-401 labeled MDA-MB-231HP, MDA-MB-231HLN, and MDA-MB-231HLM cells more brightly than MDA-MB-231 parental cells. OBP-401 killed MDA-MB-231H, MDA-MB-231HLN, and MDA-MB-231HLM cells more efficiently than MDA-MB-231P parental cells. These results indicate that OBP-401 could infect, label and then kill high-metastatic MDA-MB-231 more efficiently than low-metastatic MDA-MB-231.
Collapse
Affiliation(s)
- S Yano
- AntiCancer, Inc., San Diego, CA, USA.,Department of Surgery, University of California San Diego, CA, USA.,Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - K Takehara
- AntiCancer, Inc., San Diego, CA, USA.,Department of Surgery, University of California San Diego, CA, USA.,Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - H Kishimoto
- Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - H Tazawa
- Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan
| | - Y Urata
- Oncolys BioPharm Inc., Tokyo, Japan
| | - S Kagawa
- Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - M Bouvet
- Department of Surgery, University of California San Diego, CA, USA
| | - T Fujiwara
- Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - R M Hoffman
- AntiCancer, Inc., San Diego, CA, USA.,Department of Surgery, University of California San Diego, CA, USA
| |
Collapse
|
8
|
Suzuki D, Furukawa K, Furukawa A, Shimizu H, Otsuka M, Kato A, Yoshitomi H, Takayashiki T, Kuboki S, Takano S, Sakai N, Kagawa S, Nojima H, Miyazaki M. SUN-P144: Does the Modified Glasgow Prognostic Score have a Prognostic Role in Gallbladder Cancer? Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30487-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Furukawa A, Furukawa K, Suzuki D, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Takayashiki T, Kuboki S, Takano S, Sakai N, Kagawa S, Nojima H, Miyazaki M. MON-P233: Impact of Immunonutrition on Infectious Complications in Sarcopenic Patients Undergoing Pancreaticoduodenectomy. Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30867-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
10
|
Furukawa K, Furukawa A, Suzuki D, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Takayashiki T, Kuboki S, Takano S, Sakai N, Kagawa S, Nojima H, Miyazaki M. MON-P236: Influence Of Sarcopenia On Infectious Complications in Patients Undergoing Pancreaticoduodenectomy. Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30870-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Mori Y, Nagasaka T, Umeda Y, Shiwaku R, Inada R, Nishida N, Kishimoto H, Kagawa S, Tanioka H, Mishima H, Fujiwara T, Goel A. Hypermethylation of O6-Methylguanine-Dna Methyltransferase (Mgmt) Promoter As a Prognostic Biomarker for Stage Ii, III and Iv Colorectal Cancers. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Suzuki D, Furukawa K, Aida T, Uno H, Miyauchi Y, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Takayashiki T, Kuboki S, Takano S, Okamura D, Sakai N, Kagawa S, Miyazaki M. PP022-MON: Effects of Immunonutrition on Postoperative Complication, Stress Responses, and Cell-Mediated Immunity After Pancreaticoduodenectomy: Results from Two Randomized Controlled Studies. Clin Nutr 2014. [DOI: 10.1016/s0261-5614(14)50357-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Nemoto K, Mihara K, Nakamura A, Nagai G, Kagawa S, Suzuki T, Kondo T. Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients. Pharmacopsychiatry 2014; 47:101-4. [PMID: 24764200 DOI: 10.1055/s-0034-1372644] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
INTRODUCTION The effects of escitalopram (10 mg/d) coadministration on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, were studied in 13 Japanese psychiatric patients and compared with those of paroxetine (10 mg/d) coadministration. METHODS The patients had received 6-24 mg/d of aripiprazole for at least 2 weeks. Patients were randomly allocated to one of 2 treatment sequences: paroxetine-escitalopram (n=6) or escitalopram-paroxetine (n=7). Each sequence consisted of two 2-week phases. Plasma concentrations of aripiprazole and dehydroaripiprazole were measured using liquid chromatography with mass spectrometric detection. RESULTS Plasma concentrations of aripiprazole and the sum of aripiprazole and dehydroaripiprazole during paroxetine coadministration were 1.7-fold (95% confidence intervals [CI], 1.3-2.1, p<0.001) and 1.5-fold (95% CI 1.2-1.9, p<0.01) higher than those values before the coadministration. These values were not influenced by escitalopram coadministration (1.3-fold, 95% CI 1.1-1.5 and 1.3-fold, 95% CI 1.0-1.5). Plasma dehydroaripiprazole concentrations remained constant during the study. CONCLUSION The present study suggests that low doses of escitalopram can be safely coadministered with aripiprazole, at least from a pharmacokinetic point of view.
Collapse
Affiliation(s)
- K Nemoto
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - K Mihara
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - A Nakamura
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - G Nagai
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - S Kagawa
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - T Suzuki
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| | - T Kondo
- Department of Neuropsychiatry Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan
| |
Collapse
|
14
|
Nagatomo H, Kagawa S, Kishi Y, Takuma T, Sada A, Yamanaka KI, Abe Y, Wada Y, Takahashi M, Kono T, Kawahara M. Transcriptional Wiring for Establishing Cell Lineage Specification at the Blastocyst Stage in Cattle. Biol Reprod 2013; 88:158. [DOI: 10.1095/biolreprod.113.108993] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
15
|
Yamauchi H, Higashi T, Kagawa S, Kishibe Y, Takahashi M. Chronic hemodynamic compromise and cerebral ischemic events in asymptomatic or remote symptomatic large-artery intracranial occlusive disease. AJNR Am J Neuroradiol 2013; 34:1704-10. [PMID: 23471022 DOI: 10.3174/ajnr.a3491] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE In asymptomatic or remote symptomatic LAICOD, the risk of ischemic events is low in general, but there may be a subgroup of higher risk patients who require aggressive medical management. The purpose of this study was to determine whether chronic hemodynamic compromise is a predictor of ischemic events in asymptomatic or remote symptomatic LAICOD. MATERIALS AND METHODS We prospectively studied 51 asymptomatic, 19 coexistent asymptomatic, and 19 remote (>6 months) symptomatic patients with atherosclerotic intracranial internal carotid artery or middle cerebral artery disease by using (15)O-PET. MP was defined as decreased CBF, increased OEF, and a decreased CBF/CBV ratio. All patients were followed up for 2 years or until occurrence of stroke or TIA or death. RESULTS Bypass surgery was performed in 4 patients (2 with MP). Three cerebral ischemic events (1 TIA in an asymptomatic patient, 1 stroke, and 1 TIA in a remote symptomatic patient) occurred in the vascular territory ipsilateral to LAICOD. Kaplan-Meier analysis with censoring at the time of bypass surgery revealed that the incidence of ipsilateral ischemic events in patients with MP (2/5) was significantly higher than that in patients without MP (1/84) (log-rank test; P < .0001). The relative risk conferred by MP was 83.1 (95% confidence interval, 6.8-1017.4; P < .001). The incidence of ipsilateral ischemic events in patients with decreased CBF/CBV (2/9) was also significantly higher than that of patients without it (1/80) (P = .0001). CONCLUSIONS Chronic hemodynamic compromise may be a predictor of ischemic events in both asymptomatic and remote symptomatic LAICOD.
Collapse
Affiliation(s)
- H Yamauchi
- Division of PET Imaging, Shiga Medical Center Research Institute, Shiga, Japan
| | | | | | | | | |
Collapse
|
16
|
Ohta K, Kuwahara M, Fujisaki N, Kagawa S, Furihata M, Ohtsuki Y. Overexpressed cyclin D1 protein related to p53 and retinoblastoma proteins in transitional cell carcinoma of the urinary tract. Oncol Rep 2012; 4:97-101. [PMID: 21590019 DOI: 10.3892/or.4.1.97] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We employed immunohistochemical methods to investigate the overexpression of cyclin D1 protein as well as p53 protein and retinoblastoma protein (pRb) in 57 patients with transitional cell carcinoma (TCC) of the urinary tract, in order to determine their frequency and significance, and also association with the clinicopathological behavior of this tumor. Nuclear immunostaining with cyclin D1 antibody revealed 7 homogeneously stained tumors (12.3%), including 4 heterogeneous pRb expressions, of which only one was also positive for p53. Positive immunostaining with each antibody to p53 or pRb was obtained in 15 (26.3%) and 49 (86%) tumors, respectively. The 49 pRb-positive tumors included 6 homogeneous and 43 heterogeneous nuclear immunostaining patterns. The remaining pRb-negative 8 tumors included 5 cyclin D1-negative tumors. The prevalence of p53 staining was higher in high-grade (P<0.05) and invasive types of tumors (P<0.05) than the other types studied. On the other hand, no significant relationship was found between cyclin D1- or pRb-immunoreactivity and clinicopathological factors. These findings provide evidence for infrequent cyclin D1 protein overexpression in TCC independently associated with p53 protein and/or pRb overexpression.
Collapse
Affiliation(s)
- K Ohta
- UNIV TOKUSHIMA,SCH MED,DEPT UROL,TOKUSHIMA 770,JAPAN. KOCHI MED SCH,DEPT PATHOL 2,NANKO KU,KOCHI 783,JAPAN
| | | | | | | | | | | |
Collapse
|
17
|
Salama N, Kishimoto T, Kanayama HO, Kagawa S. Retraction. Effects of exposure to a mobile phone on sexual behavior in adult male rabbit: an observational study. Int J Impot Res 2012; 24:170. [PMID: 22622334 DOI: 10.1038/ijir.2012.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
18
|
Yamauchi H, Higashi T, Kagawa S, Nishii R, Kudo T, Sugimoto K, Okazawa H, Fukuyama H. Is misery perfusion still a predictor of stroke in symptomatic major cerebral artery disease? Brain 2012; 135:2515-26. [DOI: 10.1093/brain/aws131] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Fujiwara T, Uno F, Hashimoto Y, Shirakawa Y, Nagasaka T, Kagawa S, Urata Y. Detection of viable human circulating tumor cells using telomerase-specific GFP-expressing bioengineered adenovirus in patients with gastric cancer: A feasibility study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18 Background: The presence of circulating tumor cells (CTC) in the peripheral blood is associated with short survival and, therefore, the detection of CTC is clinically useful as prognostic factors of disease outcome and/or surrogate markers of treatment response. Recent technical advances in immunocytometric analysis and quantitative real-time PCR have made possible to detect a few CTC in the blood; however, there is no sensitive assay for detecting viable CTC. We developed a new approach to visually detect live CTC among millions of peripheral blood leukocytes using telomerase-specific replication-selective adenovirus expressing green fluorescent protein (GFP). Methods: We constructed a GFP-expressing attenuated adenovirus, in which the telomerase promoter regulates viral replication (OBP-401, TelomeScan). The detection method for viable human CTC in the peripheral blood involves a three-step procedure including the lysis of red blood cells, the subsequent addition of OBP-401 to the cell pellets, and the automated scan under the fluorescent microscope. We analyzed fresh blood samples collected from 37 patients with histologically confirmed gastric cancer. We further assessed the CTC dynamics in patients who were undergoing chemotherapy or surgery to demonstrate the clinical potential of our approach for monitoring treatment responses. Results: OBP-401 increased the signal-to-background ratio as a tumor-specific probe, because the fluorescent signal can be amplified only in viable human tumor cells by viral replication. Although the CTC level varied widely, ranging from 0 to 47 in 5-ml samples, 26 gastric cancer patients (70.3%) had more than one CTC; there was, however, no apparent relationship between CTC counts and TNM stages. Patients who had a recurrence of gastric cancer had decreased CTC counts after systemic chemotherapy. In the patients who underwent surgery, the CTC level dropped after complete resection. Conclusions: This GFP-expressing virus-based method is simple and allows precise enumeration of CTC, which might be useful for monitoring the efficacy of local and systemic treatments. [Table: see text]
Collapse
Affiliation(s)
- T. Fujiwara
- Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan
| | - F. Uno
- Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan
| | - Y. Hashimoto
- Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan
| | - Y. Shirakawa
- Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan
| | - T. Nagasaka
- Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan
| | - S. Kagawa
- Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan
| | - Y. Urata
- Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan
| |
Collapse
|
20
|
Yano S, Kagawa S, Tazawa H, Uno F, Hashimoto Y, Urata Y, Fujiwara T. Mechanistic analysis of a novel, telomerase-specific oncolytic adenovirus targeting human gastric cancer stem cells. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Watanabe Y, Kojima T, Kagawa S, Uno F, Hashimoto Y, Kyo S, Mizuguchi H, Tanaka N, Kawamura H, Ichimaru D, Urata Y, Fujiwara T. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Oncogene 2009; 29:1145-54. [DOI: 10.1038/onc.2009.415] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
22
|
Hiruma M, Kagawa S. A Case of Sporotrichosis with Numerous Fungal Elements Phagocytized by Polymorphonuclear Leukocytes/Bericht über eine Sporotrichose mit ausgeprägter Phagozytose der Pilzzellen durch Granulozyten. Mycoses 2009. [DOI: 10.1111/j.1439-0507.1986.tb03749.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Yanagawa H, Terao J, Takeda E, Takaishi Y, Kashiwada Y, Kawazoe K, Fushitani S, Tsuchiya K, Yamauchi A, Sato C, Irahara M, Kagawa S. Present status of clinic for complementary and alternative medicine at university hospitals in Japan; a case of Tokushima University Hospital. Eur J Integr Med 2008. [DOI: 10.1016/j.eujim.2008.08.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Yanagawa H, Irahara M, Kawashima S, Kagawa S. The views of doctors on registration trials in a Japanese rural area: a survey of medical institutions registered to the Tokushima Network for Clinical Trials. J Int Med Res 2008; 36:1117-22. [PMID: 18831909 DOI: 10.1177/147323000803600532] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Tokushima University Hospital has established the Tokushima Network for Clinical Trials (TNCT) to promote clinical trials in the area in collaboration with the Tokushima Medical Association. The present study investigated the views of doctors towards registration trials in the TNCT. A questionnaire was provided to 49 clinics/hospitals registered to the TNCT in 2006 and 38 (78%) responded. It revealed that 48% of doctors were aware of registration trials and 87% were favourable towards participating as investigators in them. They considered close contact with developmental drugs, advancement of therapy and the opportunity to learn about state-of-the-art treatment as benefits of participation. The main areas of difficulty included management of adverse reactions and patients' refusal to take part. Many doctors wanted more opportunity to learn about trial-related issues such as regulations. The survey indicates that the TNCT needs to develop the infrastructure and enlighten participants to promote registration trials in this rural regional area.
Collapse
Affiliation(s)
- H Yanagawa
- Clinical Trial Centre for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.
| | | | | | | | | |
Collapse
|
25
|
Chekanov S, Derrick M, Magill S, Musgrave B, Nicholass D, Repond J, Yoshida R, Mattingly MCK, Antonioli P, Bari G, Bellagamba L, Boscherini D, Bruni A, Bruni G, Cindolo F, Corradi M, Iacobucci G, Margotti A, Nania R, Polini A, Antonelli S, Basile M, Bindi M, Cifarelli L, Contin A, De Pasquale S, Sartorelli G, Zichichi A, Bartsch D, Brock I, Hartmann H, Hilger E, Jakob HP, Jüngst M, Nuncio-Quiroz AE, Paul E, Samson U, Schönberg V, Shehzadi R, Wlasenko M, Brook NH, Heath GP, Morris JD, Capua M, Fazio S, Mastroberardino A, Schioppa M, Susinno G, Tassi E, Kim JY, Ibrahim ZA, Kamaluddin B, Wan Abdullah WAT, Ning Y, Ren Z, Sciulli F, Chwastowski J, Eskreys A, Figiel J, Galas A, Gil M, Olkiewicz K, Stopa P, Zawiejski L, Adamczyk L, Bołd T, Grabowska-Bołd I, Kisielewska D, Lukasik J, Przybycień M, Suszycki L, Kotański A, Słomiński W, Behrens U, Blohm C, Bonato A, Borras K, Ciesielski R, Coppola N, Fang S, Fourletova J, Geiser A, Göttlicher P, Grebenyuk J, Gregor I, Haas T, Hain W, Hüttmann A, Januschek F, Kahle B, Katkov II, Klein U, Kötz U, Kowalski H, Lobodzinska E, Löhr B, Mankel R, Melzer-Pellmann IA, Miglioranzi S, Montanari A, Namsoo T, Notz D, Parenti A, Rinaldi L, Roloff P, Rubinsky I, Santamarta R, Schneekloth U, Spiridonov A, Szuba D, Szuba J, Theedt T, Wolf G, Wrona K, Yagües Molina AG, Youngman C, Zeuner W, Drugakov V, Lohmann W, Schlenstedt S, Barbagli G, Gallo E, Pelfer PG, Bamberger A, Dobur D, Karstens F, Vlasov NN, Bussey PJ, Doyle AT, Dunne W, Forrest M, Rosin M, Saxon DH, Skillicorn IO, Gialas I, Papageorgiu K, Holm U, Klanner R, Lohrmann E, Schleper P, Schörner-Sadenius T, Sztuk J, Stadie H, Turcato M, Foudas C, Fry C, Long KR, Tapper AD, Matsumoto T, Nagano K, Tokushuku K, Yamada S, Yamazaki Y, Barakbaev AN, Boos EG, Pokrovskiy NS, Zhautykov BO, Aushev V, Borodin M, Kadenko I, Kozulia A, Libov V, Lisovyi M, Lontkovskyi D, Makarenko I, Sorokin I, Verbytskyi A, Volynets O, Son D, de Favereau J, Piotrzkowski K, Barreiro F, Glasman C, Jimenez M, Labarga L, Del Peso J, Ron E, Soares M, Terrón J, Zambrana M, Corriveau F, Liu C, Schwartz J, Walsh R, Zhou C, Tsurugai T, Antonov A, Dolgoshein BA, Gladkov D, Sosnovtsev V, Stifutkin A, Suchkov S, Dementiev RK, Ermolov PF, Gladilin LK, Golubkov YA, Khein LA, Korzhavina IA, Kuzmin VA, Levchenko BB, Lukina OY, Proskuryakov AS, Shcheglova LM, Zotkin DS, Abt I, Caldwell A, Kollar D, Reisert B, Schmidke WB, Grigorescu G, Keramidas A, Koffeman E, Kooijman P, Pellegrino A, Tiecke H, Vázquez M, Wiggers L, Brümmer N, Bylsma B, Durkin LS, Lee A, Ling TY, Allfrey PD, Bell MA, Cooper-Sarkar AM, Devenish RCE, Ferrando J, Foster B, Korcsak-Gorzo K, Oliver K, Robertson A, Uribe-Estrada C, Walczak R, Bertolin A, Dal Corso F, Dusini S, Longhin A, Stanco L, Bellan P, Brugnera R, Carlin R, Garfagnini A, Limentani S, Oh BY, Raval A, Ukleja J, Whitmore JJ, Iga Y, D'Agostini G, Marini G, Nigro A, Cole JE, Hart JC, Abramowicz H, Ingbir R, Kananov S, Levy A, Stern A, Kuze M, Maeda J, Hori R, Kagawa S, Okazaki N, Shimizu S, Tawara T, Hamatsu R, Kaji H, Kitamura S, Ota O, Ri YD, Costa M, Ferrero MI, Monaco V, Sacchi R, Solano A, Arneodo M, Ruspa M, Fourletov S, Martin JF, Stewart TP, Boutle SK, Butterworth JM, Gwenlan C, Jones TW, Loizides JH, Wing M, Brzozowska B, Ciborowski J, Grzelak G, Kulinski P, Luzniak P, Malka J, Nowak RJ, Pawlak JM, Tymieniecka T, Ukleja A, Zarnecki AF, Adamus M, Plucinski P, Eisenberg Y, Hochman D, Karshon U, Brownson E, Danielson T, Everett A, Kçira D, Reeder DD, Ryan P, Savin AA, Smith WH, Wolfe H, Bhadra S, Catterall CD, Cui Y, Hartner G, Menary S, Noor U, Standage J, Whyte J. Inclusive K(S);(0)K(S);(0) resonance production in ep collisions at HERA. Phys Rev Lett 2008; 101:112003. [PMID: 18851276 DOI: 10.1103/physrevlett.101.112003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2008] [Indexed: 05/26/2023]
Abstract
Inclusive K_{S};{0}K_{S};{0} production in ep collisions at the DESY ep collider HERA was studied with the ZEUS detector using an integrated luminosity of 0.5 fb;{-1}. Enhancements in the mass spectrum were observed and are attributed to the production of f_{2}(1270)/a_{2};{0}(1320), f_{2};{'}(1525) and f_{0}(1710). Masses and widths were obtained using a fit which takes into account theoretical predictions based on SU(3) symmetry arguments, and are consistent with the Particle Data Group values. The f_{0}(1710) state, which has a mass consistent with a glueball candidate, was observed with a statistical significance of 5 standard deviations. However, if this state is the same as that seen in gammagamma-->K_{S};{0}K_{S};{0}, it is unlikely to be a pure glueball state.
Collapse
Affiliation(s)
- S Chekanov
- Argonne National Laboratory, Argonne, Illinois 60439-4815, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Endo Y, Sakai R, Ouchi M, Onimatsu H, Hioki M, Kagawa S, Uno F, Watanabe Y, Urata Y, Tanaka N, Fujiwara T. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 2007; 27:2375-81. [PMID: 17982491 DOI: 10.1038/sj.onc.1210884] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Dendritic cells (DCs) are the most potent antigen-presenting cells and acquire cellular antigens and danger signals from dying cells to initiate antitumor immune responses via direct cell-to-cell interaction and cytokine production. The optimal forms of tumor cell death for priming DCs for the release of danger signals are not fully understood. OBP-301 (Telomelysin) is a telomerase-specific replication-competent adenovirus that induces selective E1 expression and exclusively kills human cancer cells. Here, we show that OBP-301 replication produced the endogenous danger signaling molecule, uric acid, in infected human tumor cells, which in turn stimulated DCs to produce interferon-gamma (IFN-gamma) and interleukin 12 (IL-12). Subsequently, IFN-gamma release upregulated the endogenous expression of the proteasome activator PA28 in tumor cells and resulted in the induction of cytotoxic T-lymphocytes. Our data suggest that virus-mediated oncolysis might be the effective stimulus for immature DCs to induce specific activity against human cancer cells.
Collapse
Affiliation(s)
- Y Endo
- Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Fukumori T, Oka N, El-Moula M, Nakanishi R, Taue R, Kishimoto T, Izaki H, Takahashi M, Kagawa S, Kanayama H. MP-16.09: Galectin-3 is overexpressed in renal cell carcinoma and it regulates immune suppression through the induction of apoptosis of cytotoxic T cells. Urology 2007. [DOI: 10.1016/j.urology.2007.06.469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Izaki H, El-Moula M, Fukumori T, Takahashi M, Taue R, Kishimoto T, Kagawa S, Kanayama H. MP-06.04: Hem-o-lok polymer ligating clip for vascular control of the renal pedicle: points of controversy. Urology 2007. [DOI: 10.1016/j.urology.2007.06.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
29
|
Taue R, Izaki H, Gad El-Moul M, Kishimoto T, Fukumori T, Takahashi M, Kagawa S, Kanayama H. POS-03.33: Transperitoneal versus retroperitoneal laparoscopic radical nephrectomy: patient selection and perioperative outcomes: a single-center experience. Urology 2007. [DOI: 10.1016/j.urology.2007.06.1022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Affiliation(s)
- F Teraishi
- Department of Surgical Oncology, Division of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
| | | | | | | | | | | |
Collapse
|
31
|
Usami M, Akaza H, Arai Y, Hirano Y, Kagawa S, Kanetake H, Naito S, Sumiyoshi Y, Takimoto Y, Terai A, Yoshida H, Ohashi Y. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis 2007; 10:194-201. [PMID: 17199134 DOI: 10.1038/sj.pcan.4500934] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
To compare combination therapy with bicalutamide 80 mg and a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A alone in Japanese men with untreated advanced prostate cancer. A total of 205 patients with stage C/D prostate cancer were randomized to either LHRH-A+once-daily oral bicalutamide 80 mg or placebo. Primary study variables have been reported previously. Secondary variables included: time to achieve prostate-specific antigen < or = 4 ng/ml, time-to-treatment failure (TTTF), time-to-disease progression (TTP), overall survival (OS), adverse events and adverse drug reactions. Following combination therapy with bicalutamide 80 mg, there were significant (P<0.001) advantages over LHRH-A alone in terms of TTTF and TTP, but the difference in the interim OS was not statistically significant. First-line combination therapy with bicalutamide 80 mg in Japanese patients with advanced prostate cancer offers significant benefits over LHRH-A alone, with respect to TTTF and TTP. Follow-up for OS continues.
Collapse
Affiliation(s)
- M Usami
- Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Chekanov S, Derrick M, Krakauer D, Loizides JH, Magill S, Miglioranzi S, Musgrave B, Repond J, Yoshida R, Mattingly MCK, Antonioli P, Bari G, Basile M, Bellagamba L, Boscherini D, Bruni A, Bruni G, Cara Romeo G, Cifarelli L, Cindolo F, Contin A, Corradi M, De Pasquale S, Giusti P, Iacobucci G, Margiotti A, Montanari A, Nania R, Palmonari F, Pesci A, Sartorelli G, Zichichi A, Aghuzumtsyan G, Bartsch D, Brock I, Goers S, Hartmann H, Hilger E, Irrgang P, Jakob HP, Kind O, Meyer U, Paul E, Rautenberg J, Renner R, Stifutkin A, Tandler J, Voss KC, Wang M, Weber A, Bailey DS, Brook NH, Cole JE, Heath GP, Namsoo T, Robins S, Wing M, Capua M, Mastroberardino A, Schioppa M, Susinno G, Kim JY, Kim YK, Lee JH, Lim IT, Pac MY, Caldwell A, Helbich M, Liu X, Mellado B, Ning Y, Paganis S, Ren Z, Schmidke WB, Sciulli F, Chwastowski J, Eskreys A, Figiel J, Galas A, Olkiewicz K, Stopa P, Zawiejski L, Adamczyk L, Bołd T, Grabowska-Bołd I, Kisielewska D, Kowal AM, Kowal M, Kowalski T, Przybycień M, Suszycki L, Szuba D, Szuba J, Kotański A, Słomiński W, Adler V, Behrens U, Bloch I, Borras K, Chiochia V, Dannheim D, Drews G, Fourletova J, Fricke U, Geiser A, Göttlicher P, Gutsche O, Haas T, Hain W, Hillert S, Kahle B, Kötz U, Kowalski H, Kramberger G, Labes H, Lelas D, Lim H, Löhr B, Mankel R, Melzer-Pellmann IA, Nguyen CN, Notz D, Nucio-Quiroz AE, Polini A, Raval A, Rurua L, Schneekloth U, Stösslein U, Wolf G, Youngman C, Zeuner W, Schlenstedt S, Barbagli G, Gallo E, Genta C, Pelfer PG, Bamberger A, Benen A, Karstens F, Dobur D, Vlasov NN, Bell M, Bussey PJ, Doyle AT, Ferrando J, Hamilton J, Hanlon S, Saxon DH, Skillicorn IO, Gialas I, Carli T, Gosau T, Holm U, Krumnack N, Lohrmann E, Milite M, Salehi H, Schleper P, Stonjek S, Wichmann K, Wick K, Ziegler A, Ziegler A, Collins-Tooth C, Foudas C, Gonçalo R, Long KR, Tapper AD, Cloth P, Filges D, Kataoka M, Nagano K, Tokushuku K, Yamada S, Yamazaki Y, Barakbaev AN, Boos EG, Pokrovskiy NS, Zhautykov BO, Son D, Piotrzkowski K, Barreiro F, Glasman C, González O, Labarga L, del Peso J, Tassi E, Terrón J, Vázquez M, Zambrana M, Barbi M, Corriveau F, Gliga S, Lainesse J, Padhi S, Stairs DG, Walsh R, Tsurugai T, Antonov A, Danilov P, Dolgoshein BA, Gladkov D, Sosnovtsev V, Suchkov S, Dementiev RK, Ermolov PF, Golubkov YA, Katkov II, Khein LA, Korzhavina IA, Kuzmin VA, Levchenko BB, Lukina OY, Proskuryakov AS, Shcheglova LM, Zotkin SA, Coppola N, Grijpink S, Koffeman E, Kooijman P, Maddox E, Pellegrino A, Schagen S, Tiecke H, Velthuis JJ, Wiggers L, de Wolf E, Brümmer N, Bylsma B, Durkin LS, Ling TY, Cooper-Sarkar AM, Cottrell A, Devenish RCE, Foster B, Grzelak G, Gwenlan C, Patel S, Straub PB, Walczak R, Bertolin A, Brugnera R, Carlin R, Dal Corso F, Dusini S, Garfagnini A, Limentani S, Longhin A, Parenti A, Posocco M, Stanco L, Turcato M, Heaphy EA, Metlica F, Oh BY, Whitmore JJ, Iga Y, D’Agostini G, Marini G, Nigro A, Cormack C, Hart JC, McCubbin NA, Heusch C, Park IH, Pavel N, Abramowicz H, Gabareen A, Kananov S, Kreisel A, Levy A, Kuze M, Fusayasu T, Kagawa S, Kohno T, Tawara T, Yamashita T, Hamatsu R, Hirose T, Inuzuka M, Kaji H, Kitamura S, Matsuzawa K, Ferrero MI, Monaco V, Sacchi R, Solano A, Arneodo M, Ruspa M, Koop T, Martin JF, Mirea A, Butterworth JM, Hall-Wilton R, Jones TW, Lightwood MS, Sutton MR, Targett-Adams C, Ciborowski J, Ciesielski R, Łużniak P, Nowak RJ, Pawlak JM, Sztuk J, Tymieniecka T, Ukleja A, Ukleja J, Żarnecki AF, Adamus M, Plucinski P, Eisenberg Y, Gladilin LK, Hochman D, Karshon U, Riveline M, Kçira D, Lammers S, Li L, Reeder DD, Rosin M, Savin AA, Smith WH, Deshpande A, Dhawan S, Bhadra S, Catterall CD, Fourletov S, Hartner G, Menary S, Soares M, Standage J. Erratum: Bottom photoproduction measured using decays into muons in dijet events inepcollisions ats=318 GeV[Phys. Rev. D70, 012008 (2004)]. Int J Clin Exp Med 2006. [DOI: 10.1103/physrevd.74.059906] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
33
|
Fujiwara T, Kagawa S, Kawamura H, Nagai K, Nohara R, Tanaka N, Urata Y. A novel telomerase-specific oncolytic virotherapy for human cancer: preclinical evaluation of safety, biodistribution, and efficacy. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13057 Background: Replication-selective tumor-specific viruses present a novel approach for treating neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is considered to be a critical step in carcinogenesis and its activity is closely correlated with human telomerase reverse transcriptase (hTERT) expression. We constructed an adenovirus 5 vector (Telomelysin [OBP-301]), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an IRES. Methods: We examined the antitumor effect of Telomelysin as a single agent or in combination with systemic administration of chemotherapeutic drugs such as docetaxel in tumor xenograft models. IND-supporting preclinical toxicology and pharmacodynamic studies were also performed to characterize the safety, pharmacokinetics and biological activity of Telomelysin. Results: Telomelysin replicated efficiently and induced marked cell killing in a panel of human cancer cell lines derived from various organs, whereas replication as well as cytotoxicity was highly attenuated in normal human cells lacking telomerase activity. In nu/nu mice carrying subcutaneous human tumor xenografts, intratumoral injection of Telomelysin resulted in a significant inhibition of tumor growth, which was significantly enhanced in combination with systemic administration of docetaxel. Moreover, Telomelysin replication in the distant, un-injected tumors was demonstrated. Viral DNA was identified in tissues outside of the injection site; however, toxicology studies including pathological examinations in mice and cotton rats demonstrated that local injection of Telomelysin could be well-tolerated with an acceptable safety profile. Conclusions: The hTERT promoter confers competence for selective replication of Telomelysin in human cancer cells, an outcome that has important implications for the treatment of human cancers. Telomelysin has been already manufactured under GMP conditions for initial clinical trials. Upon FDA approval, a phase I dose-escalation study of intratumoral injection of Telomelysin for various solid tumors will be started. [Table: see text]
Collapse
Affiliation(s)
- T. Fujiwara
- Okayama University, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan; Okayama University Graduate School, Okayama, Japan
| | - S. Kagawa
- Okayama University, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan; Okayama University Graduate School, Okayama, Japan
| | - H. Kawamura
- Okayama University, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan; Okayama University Graduate School, Okayama, Japan
| | - K. Nagai
- Okayama University, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan; Okayama University Graduate School, Okayama, Japan
| | - R. Nohara
- Okayama University, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan; Okayama University Graduate School, Okayama, Japan
| | - N. Tanaka
- Okayama University, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan; Okayama University Graduate School, Okayama, Japan
| | - Y. Urata
- Okayama University, Okayama, Japan; Oncolys BioPharma, Inc., Tokyo, Japan; Okayama University Graduate School, Okayama, Japan
| |
Collapse
|
34
|
Kagawa S, Fujiwara T, Saijo Y, Nukiwa T, Yoshimura K, Nakamura H, Kato H, Chada S, Tanaka N. A multicenter phase I study of adenoviral p53 in Japanese patients with advanced non-small cell lung cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2564 Adenovirus expressing p53 gene, Advexin (A), has shown antitumor activity in a variety of human cancer in preclinical and clinical studies. The goals of this study were to determine the feasibility, safety, humoral immune response, and biological activity of multiple intratumoral injections of A and to characterize the pharmacokinetics of A in Japanese patients with advanced non-small cell lung cancer (NSCLC). Fifteen patients with histologically confirmed NSCLC and p53 mutations were enrolled into this phase I trial. Nine patients received escalating dose levels of A (1 × 109 to 1 × 1011 plaque-forming units [PFU]) as monotherapy once every 4 weeks. Six patients were treated on a 28-day schedule with A in combination with intravenous administration of cisplatin (80 mg/m2). Patients were monitored for toxicity, tumor response, antibody formation, and vector distribution. Fifteen patients received a total of 63 intratumoral injections of A without dose-limiting toxicity. The most common treatment-related toxicity was a transient fever. Thirteen of 15 patients were assessable for efficacy; one patient had a partial response (squamous cell carcinoma at the carina), 10 patients had stable disease, with three lasting > 9 months, and 2 patients had progressive disease. Distribution studies revealed that the vector was detected in the gargle and plasma, but rarely in the urine. Despite of the presence of neutralizing anti-adenovirus antibody, specific p53 transgene expression was detected in biopsied tumor tissues throughout the period of treatment using reverse-transcriptase polymerase chain reaction We conclude that multiple courses of intratumoral A injection alone or in combination with intravenous administration of cisplatin were feasible and well tolerated in advanced NSCLC patients, and appeared to provide clinical benefit. [Table: see text]
Collapse
Affiliation(s)
- S. Kagawa
- Okayama University Hospital, Okayama, Japan; Tohoku University, Sendai, Japan; Jikei University School of Medicine, Tokyo, Japan; Tokyo Medical University, Tokyo, Japan; Introgen Therapeutics, Inc., Houston, TX; Okayama University Graduate School, Okayama, Japan
| | - T. Fujiwara
- Okayama University Hospital, Okayama, Japan; Tohoku University, Sendai, Japan; Jikei University School of Medicine, Tokyo, Japan; Tokyo Medical University, Tokyo, Japan; Introgen Therapeutics, Inc., Houston, TX; Okayama University Graduate School, Okayama, Japan
| | - Y. Saijo
- Okayama University Hospital, Okayama, Japan; Tohoku University, Sendai, Japan; Jikei University School of Medicine, Tokyo, Japan; Tokyo Medical University, Tokyo, Japan; Introgen Therapeutics, Inc., Houston, TX; Okayama University Graduate School, Okayama, Japan
| | - T. Nukiwa
- Okayama University Hospital, Okayama, Japan; Tohoku University, Sendai, Japan; Jikei University School of Medicine, Tokyo, Japan; Tokyo Medical University, Tokyo, Japan; Introgen Therapeutics, Inc., Houston, TX; Okayama University Graduate School, Okayama, Japan
| | - K. Yoshimura
- Okayama University Hospital, Okayama, Japan; Tohoku University, Sendai, Japan; Jikei University School of Medicine, Tokyo, Japan; Tokyo Medical University, Tokyo, Japan; Introgen Therapeutics, Inc., Houston, TX; Okayama University Graduate School, Okayama, Japan
| | - H. Nakamura
- Okayama University Hospital, Okayama, Japan; Tohoku University, Sendai, Japan; Jikei University School of Medicine, Tokyo, Japan; Tokyo Medical University, Tokyo, Japan; Introgen Therapeutics, Inc., Houston, TX; Okayama University Graduate School, Okayama, Japan
| | - H. Kato
- Okayama University Hospital, Okayama, Japan; Tohoku University, Sendai, Japan; Jikei University School of Medicine, Tokyo, Japan; Tokyo Medical University, Tokyo, Japan; Introgen Therapeutics, Inc., Houston, TX; Okayama University Graduate School, Okayama, Japan
| | - S. Chada
- Okayama University Hospital, Okayama, Japan; Tohoku University, Sendai, Japan; Jikei University School of Medicine, Tokyo, Japan; Tokyo Medical University, Tokyo, Japan; Introgen Therapeutics, Inc., Houston, TX; Okayama University Graduate School, Okayama, Japan
| | - N. Tanaka
- Okayama University Hospital, Okayama, Japan; Tohoku University, Sendai, Japan; Jikei University School of Medicine, Tokyo, Japan; Tokyo Medical University, Tokyo, Japan; Introgen Therapeutics, Inc., Houston, TX; Okayama University Graduate School, Okayama, Japan
| |
Collapse
|
35
|
Takahashi M, Yang XJ, McWhinney S, Sano N, Eng C, Kagawa S, Teh BT, Kanayama HO. cDNA microarray analysis assists in diagnosis of malignant intrarenal pheochromocytoma originally masquerading as a renal cell carcinoma. J Med Genet 2006; 42:e48. [PMID: 16061554 PMCID: PMC1736113 DOI: 10.1136/jmg.2005.031708] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Intrarenal pheochromocytoma (paraganglioma) is a very rare tumour. Its diagnosis is often difficult to establish because of its rarity and its histological similarity to renal cell carcinoma (RCC). Recently, we examined the molecular signatures of different subtypes of kidney tumours by using cDNA microarray. The signature pattern for one tumour, which was originally diagnosed as granular cell RCC, was clearly distinct from that of any other subtype of kidney tumour, and led us to re-evaluate the case. Haematoxylin and eosin staining revealed histological features suggestive of pheochromocytoma, and immunohistochemical studies showed positive staining for neuroendocrine markers but not for keratin. A germline missense mutation, D119E, in the familial paraganglioma related gene succinate dehydrogenase subunit D (SDHD), was subsequently identified. The treatment modality was revised and radiotherapy was given, to which the patient responded, leading to a reduction in tumour size of 25% within the first month. To our knowledge, this is the first report of an intrarenal pheochromocytoma that was diagnosed with the assistance of cDNA microarray analysis.
Collapse
|
36
|
Ewis AA, Lee J, Naroda T, Sano T, Kagawa S, Iwamoto T, Shinka T, Shinohara Y, Ishikawa M, Baba Y, Nakahori Y. Prostate cancer incidence varies among males from different Y-chromosome lineages. Prostate Cancer Prostatic Dis 2006; 9:303-9. [PMID: 16683011 DOI: 10.1038/sj.pcan.4500876] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The incidence rate of prostate cancer in African-American males is two times higher than Caucasian men and ten times higher than Japanese men. The geographical specificity of Y haplogroups implies that males from different ethnic groups undoubtedly have various Y lineages with different Y-chromosomal characteristics that may affect their susceptibility or resistance to such a male-specific cancer. To confirm this hypothesis we studied the Y-chromosomal haplogroups of 92 Japanese prostate cancer patients comparing them with randomly selected 109 unrelated healthy Japanese male controls who were confirmed to be residents of the same geographical area. Males could be classified using three binary Y-chromosome markers (sex-determining region Y (SRY), YAP, 47z) into four haplogroups DE, O2b(*), O2b1, and untagged group. Our results confirmed that prostate cancer incidence varies among males from different Y-chromosome lineages. Males from DE and the untagged haplogroups are at a significantly higher risk to develop prostate cancer than O2b(*) and O2b1 haplogroups (P=0.01), odds ratio 2.17 and 95% confidence interval (1.16-4.07). Males from haplogroup DE are over-represented in the patient group showing a percentage of 41.3%. The underlying possible causes of susceptibility variations of different Y lineages for such a male-specific cancer tumorigenesis are discussed. These findings explain the lower incidence of prostate cancer in Japanese and other South East Asian males than other populations. To our knowledge, this is the first reliable study examining the association between prostate cancer and Y-chromosomal haplogroups, comparing prostate cancer patients with carefully selected matched controls.
Collapse
Affiliation(s)
- A A Ewis
- Health Technology Research Center, National Institute of Advanced Industrial Science and Technology, Hayashi-cho 2217-14, Takamatsu, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Kagawa S, Nagano Y, Tazumi A, Murayama O, Millar BC, Moore JE, Matsuda M. Nucleotide Sequencing and Analysis of 16S rDNA and 16S-23S rDNA Internal Spacer Region (ISR) of Taylorella equigenitalis, as an Important Pathogen for Contagious Equine Metritis (CEM). Vet Res Commun 2006; 30:343-55. [PMID: 16502103 DOI: 10.1007/s11259-006-3304-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/01/2004] [Indexed: 10/25/2022]
Abstract
The primer set for 16S rDNA amplified an amplicon of about 1500 bp in length for three strains of Taylorella equigenitalis (NCTC11184(T), Kentucky188 and EQ59). Sequence differences of the 16S rDNA among the six sequences, including three reference sequences, occurred at only a few nucleotide positions and thus, an extremely high sequence similarity of the 16S rDNA was first demonstrated among the six sequences. In addition, the primer set for 16S-23S rDNA internal spacer region (ISR) amplified two amplicons about 1300 bp and 1200 bp in length for the three strains. The ISRs were estimated to be about 920 bp in length for large ISR-A and about 830 bp for small ISR-B. Sequence alignment of the ISR-A and ISR-B demonstrated about 10 base differences between NCTC11184(T) and EQ59 and between Kentucky188 and EQ59. However, only minor sequence differences were demonstrated between the ISR-A and ISR-B from NCTC11184(T) and Kentucky188, respectively. A typical order of the intercistronic tRNAs with the 29 nucleotide spacer of 5'-16S rDNA-tRNA(Ile)-tRNA(Ala)-23S rDNA-3' was demonstrated in the all ISRs. The ISRs may be useful for the discrimination amongst isolates of T. equigenitalis if sequencing is employed.
Collapse
Affiliation(s)
- S Kagawa
- Laboratory of Molecular Biology, School of Environmental Health Sciences, Azabu University, Fuchinobe 1-17-71, Sagamihara, 229-8501, Japan
| | | | | | | | | | | | | |
Collapse
|
38
|
Matsuda M, Tazumi A, Kagawa S, Sekizuka T, Murayama O, Moore JE, Millar BC. Homogeneity of the 16S rDNA sequence among geographically disparate isolates of Taylorella equigenitalis. BMC Vet Res 2006; 2:1. [PMID: 16398935 PMCID: PMC1360666 DOI: 10.1186/1746-6148-2-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2005] [Accepted: 01/06/2006] [Indexed: 11/30/2022] Open
Abstract
Background At present, six accessible sequences of 16S rDNA from Taylorella equigenitalis (T. equigenitalis) are available, whose sequence differences occur at a few nucleotide positions. Thus it is important to determine these sequences from additional strains in other countries, if possible, in order to clarify any anomalies regarding 16S rDNA sequence heterogeneity. Here, we clone and sequence the approximate full-length 16S rDNA from additional strains of T. equigenitalis isolated in Japan, Australia and France and compare these sequences to the existing published sequences. Results Clarification of any anomalies regarding 16S rDNA sequence heterogeneity of T. equigenitalis was carried out. When cloning, sequencing and comparison of the approximate full-length 16S rDNA from 17 strains of T. equigenitalis isolated in Japan, Australia and France, nucleotide sequence differences were demonstrated at the six loci in the 1,469 nucleotide sequence. Moreover, 12 polymorphic sites occurred among 23 sequences of the 16S rDNA, including the six reference sequences. Conclusion High sequence similarity (99.5% or more) was observed throughout, except from nucleotide positions 138 to 501 where substitutions and deletions were noted.
Collapse
Affiliation(s)
- M Matsuda
- Laboratory of Molecular Biology, School of Environmental Health Sciences, Azabu University, Fuchinobe 1-17-71, Sagamihara 229-8501, Japan
| | - A Tazumi
- Laboratory of Molecular Biology, School of Environmental Health Sciences, Azabu University, Fuchinobe 1-17-71, Sagamihara 229-8501, Japan
| | - S Kagawa
- Laboratory of Molecular Biology, School of Environmental Health Sciences, Azabu University, Fuchinobe 1-17-71, Sagamihara 229-8501, Japan
| | - T Sekizuka
- Laboratory of Molecular Biology, School of Environmental Health Sciences, Azabu University, Fuchinobe 1-17-71, Sagamihara 229-8501, Japan
| | - O Murayama
- Laboratory of Molecular Biology, School of Environmental Health Sciences, Azabu University, Fuchinobe 1-17-71, Sagamihara 229-8501, Japan
| | - JE Moore
- Department of Bacteriology, Northern Ireland Public Health Laboratory, Belfast City Hospital, Belfast BT9 7AD, Northern Ireland, UK
| | - BC Millar
- Department of Bacteriology, Northern Ireland Public Health Laboratory, Belfast City Hospital, Belfast BT9 7AD, Northern Ireland, UK
- School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Co. Londonderry, BT52 1SA, Northern Ireland, UK
| |
Collapse
|
39
|
Aihara E, Kagawa S, Hayashi M, Takeuchi K. ACE inhibitor and AT1 antagonist stimulate duodenal HCO3- secretion mediated by a common pathway - involvement of PG, NO and bradykinin. J Physiol Pharmacol 2005; 56:391-406. [PMID: 16204762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 03/17/2005] [Accepted: 07/04/2005] [Indexed: 05/04/2023]
Abstract
Recent study demonstrated that duodenal HCO3- secretion is affected by modulation of the renin-angiotensin system. We examined the effects of enalapril (angiotensin-converting enzyme (ACE) inhibitor) or losartan (angiotensin AT1 receptor antagonist) on duodenal HCO3- secretion in rats and investigated the mechanisms involved in the renin-angiotensin system-related HCO3- response. A proximal duodenal loop was perfused with saline, and HCO3- secretion was measured at pH 7.0 using a pH-stat method and by adding 2 mM HCl. Enalapril increased the HCO3- secretion in a dose-dependent manner, with a decrease in arterial blood pressure (MBP), and these effects were significantly attenuated by pretreatment with indomethacin, L-NAME and FR172357 (a selective bradykinin B2 receptor antagonist). Although losartan alone did not affect the HCO3- secretion, despite reducing MBP, the agent dose-dependently increased the HCO3- secretion in the presence of angiotensin II, and this response was totally antagonized by prior administration of FR172357, indomethacin and L-NAME. Bradykinin also dose-dependently increased the HCO3- secretion with no change in MBP, though transient, and again the effects were blocked by indomethacin, L-NAME and FR172357. Both prostaglandin (PG) E2 and the nitric oxide (NO) donor NOR-3 also increased the HCO3- secretion, the latter effect being inhibited by indomethacin. These results suggest that both an ACE inhibitor and AT1 antagonist (in the presence of angiotensin II) increase duodenal HCO3- secretion via a common pathway, involving bradykinin, NO and PGs. It is also assumed that bradykinin releases NO locally, which in turns stimulates HCO3- secretion mediated by PGs.
Collapse
Affiliation(s)
- E Aihara
- Department of Pharmacology and Experimental Therapeutic Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto, Japan
| | | | | | | |
Collapse
|
40
|
Akaza H, Yoshida H, Takimoto Y, Kagawa S, Terai A, Arai Y, Usami M, Naito S, Kanetake H, Ohashi Y. Bicalutamide 80 mg in combination with an LHRHa versus LHRHa monotherapy in previously untreated advanced prostate cancer: a double-blind, placebo-controlled trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4648] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Akaza
- Institute of Clin Medicine, Univ of Tsukuba, Ibaraki, Japan; Syowa Univ Hosp, Tokyo, Japan; Nihon Univ Itabashi Hosp, Tokyo, Japan; Tokushima Univ Hosp, Tokushima, Japan; Kurashiki Central Hosp, Okayama, Japan; Tohoku Univ Sch of Medicine, Miyagi, Japan; Osaka Medcl Ctr for Cancer & CV Diseases, Osaka, Japan; Kyushu Univ Hosp, Fukuoka, Japan; Nagasaki Univ Sch of Medicine, Nagasaki, Japan; Sch of Health Sciences & Nursing, Univ of Tokyo, Tokyo, Japan
| | - H. Yoshida
- Institute of Clin Medicine, Univ of Tsukuba, Ibaraki, Japan; Syowa Univ Hosp, Tokyo, Japan; Nihon Univ Itabashi Hosp, Tokyo, Japan; Tokushima Univ Hosp, Tokushima, Japan; Kurashiki Central Hosp, Okayama, Japan; Tohoku Univ Sch of Medicine, Miyagi, Japan; Osaka Medcl Ctr for Cancer & CV Diseases, Osaka, Japan; Kyushu Univ Hosp, Fukuoka, Japan; Nagasaki Univ Sch of Medicine, Nagasaki, Japan; Sch of Health Sciences & Nursing, Univ of Tokyo, Tokyo, Japan
| | - Y. Takimoto
- Institute of Clin Medicine, Univ of Tsukuba, Ibaraki, Japan; Syowa Univ Hosp, Tokyo, Japan; Nihon Univ Itabashi Hosp, Tokyo, Japan; Tokushima Univ Hosp, Tokushima, Japan; Kurashiki Central Hosp, Okayama, Japan; Tohoku Univ Sch of Medicine, Miyagi, Japan; Osaka Medcl Ctr for Cancer & CV Diseases, Osaka, Japan; Kyushu Univ Hosp, Fukuoka, Japan; Nagasaki Univ Sch of Medicine, Nagasaki, Japan; Sch of Health Sciences & Nursing, Univ of Tokyo, Tokyo, Japan
| | - S. Kagawa
- Institute of Clin Medicine, Univ of Tsukuba, Ibaraki, Japan; Syowa Univ Hosp, Tokyo, Japan; Nihon Univ Itabashi Hosp, Tokyo, Japan; Tokushima Univ Hosp, Tokushima, Japan; Kurashiki Central Hosp, Okayama, Japan; Tohoku Univ Sch of Medicine, Miyagi, Japan; Osaka Medcl Ctr for Cancer & CV Diseases, Osaka, Japan; Kyushu Univ Hosp, Fukuoka, Japan; Nagasaki Univ Sch of Medicine, Nagasaki, Japan; Sch of Health Sciences & Nursing, Univ of Tokyo, Tokyo, Japan
| | - A. Terai
- Institute of Clin Medicine, Univ of Tsukuba, Ibaraki, Japan; Syowa Univ Hosp, Tokyo, Japan; Nihon Univ Itabashi Hosp, Tokyo, Japan; Tokushima Univ Hosp, Tokushima, Japan; Kurashiki Central Hosp, Okayama, Japan; Tohoku Univ Sch of Medicine, Miyagi, Japan; Osaka Medcl Ctr for Cancer & CV Diseases, Osaka, Japan; Kyushu Univ Hosp, Fukuoka, Japan; Nagasaki Univ Sch of Medicine, Nagasaki, Japan; Sch of Health Sciences & Nursing, Univ of Tokyo, Tokyo, Japan
| | - Y. Arai
- Institute of Clin Medicine, Univ of Tsukuba, Ibaraki, Japan; Syowa Univ Hosp, Tokyo, Japan; Nihon Univ Itabashi Hosp, Tokyo, Japan; Tokushima Univ Hosp, Tokushima, Japan; Kurashiki Central Hosp, Okayama, Japan; Tohoku Univ Sch of Medicine, Miyagi, Japan; Osaka Medcl Ctr for Cancer & CV Diseases, Osaka, Japan; Kyushu Univ Hosp, Fukuoka, Japan; Nagasaki Univ Sch of Medicine, Nagasaki, Japan; Sch of Health Sciences & Nursing, Univ of Tokyo, Tokyo, Japan
| | - M. Usami
- Institute of Clin Medicine, Univ of Tsukuba, Ibaraki, Japan; Syowa Univ Hosp, Tokyo, Japan; Nihon Univ Itabashi Hosp, Tokyo, Japan; Tokushima Univ Hosp, Tokushima, Japan; Kurashiki Central Hosp, Okayama, Japan; Tohoku Univ Sch of Medicine, Miyagi, Japan; Osaka Medcl Ctr for Cancer & CV Diseases, Osaka, Japan; Kyushu Univ Hosp, Fukuoka, Japan; Nagasaki Univ Sch of Medicine, Nagasaki, Japan; Sch of Health Sciences & Nursing, Univ of Tokyo, Tokyo, Japan
| | - S. Naito
- Institute of Clin Medicine, Univ of Tsukuba, Ibaraki, Japan; Syowa Univ Hosp, Tokyo, Japan; Nihon Univ Itabashi Hosp, Tokyo, Japan; Tokushima Univ Hosp, Tokushima, Japan; Kurashiki Central Hosp, Okayama, Japan; Tohoku Univ Sch of Medicine, Miyagi, Japan; Osaka Medcl Ctr for Cancer & CV Diseases, Osaka, Japan; Kyushu Univ Hosp, Fukuoka, Japan; Nagasaki Univ Sch of Medicine, Nagasaki, Japan; Sch of Health Sciences & Nursing, Univ of Tokyo, Tokyo, Japan
| | - H. Kanetake
- Institute of Clin Medicine, Univ of Tsukuba, Ibaraki, Japan; Syowa Univ Hosp, Tokyo, Japan; Nihon Univ Itabashi Hosp, Tokyo, Japan; Tokushima Univ Hosp, Tokushima, Japan; Kurashiki Central Hosp, Okayama, Japan; Tohoku Univ Sch of Medicine, Miyagi, Japan; Osaka Medcl Ctr for Cancer & CV Diseases, Osaka, Japan; Kyushu Univ Hosp, Fukuoka, Japan; Nagasaki Univ Sch of Medicine, Nagasaki, Japan; Sch of Health Sciences & Nursing, Univ of Tokyo, Tokyo, Japan
| | - Y. Ohashi
- Institute of Clin Medicine, Univ of Tsukuba, Ibaraki, Japan; Syowa Univ Hosp, Tokyo, Japan; Nihon Univ Itabashi Hosp, Tokyo, Japan; Tokushima Univ Hosp, Tokushima, Japan; Kurashiki Central Hosp, Okayama, Japan; Tohoku Univ Sch of Medicine, Miyagi, Japan; Osaka Medcl Ctr for Cancer & CV Diseases, Osaka, Japan; Kyushu Univ Hosp, Fukuoka, Japan; Nagasaki Univ Sch of Medicine, Nagasaki, Japan; Sch of Health Sciences & Nursing, Univ of Tokyo, Tokyo, Japan
| |
Collapse
|
41
|
Tsunemitsu Y, Kagawa S, Tokunaga N, Otani S, Umeoka T, Roth JA, Fang B, Tanaka N, Fujiwara T. Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut 2004; 53:554-60. [PMID: 15016751 PMCID: PMC1774013 DOI: 10.1136/gut.2003.021683] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Gene therapy is an innovative therapeutic approach for cancer. An adenoviral vector expressing the tumour suppressor p53 gene (Ad/p53) is currently under clinical evaluation for various cancers. We recently developed a binary adenoviral vector system that can express the strong proapoptotic gene Bax (Ad/PGK-GV16+Ad/GT-Bax: Ad/Bax). AIMS To evaluate the potential of Bax gene therapy for gastric cancer, we assessed its antitumour effect in comparison with that of p53. METHODS The human gastric cancer cell lines MKN-1, MKN-7, MKN-28, and MKN-45 were treated with Ad/Bax or Ad/p53, and cell viability, transgene expression, and caspase activation were assessed in vitro. To compare the antitumour effects of Ad/Bax and Ad/p53 treatment in vivo, subcutaneous tumours and peritoneal dissemination of MKN-45 cells were generated in nude mice. Each mouse underwent intratumoral or intraperitoneal administration of viruses and the growth of implanted tumours was observed after treatment. RESULTS Treatment with Ad/Bax and Ad/p53 resulted in marked Bax and p53 protein expression and effective apoptosis induction in MKN-1, MKN-7, and MKN-28 cells in vitro. In contrast, MKN-45 cells showed resistance to Ad/p53 and only treatment with Ad/Bax resulted in activation of caspase 3 expression and massive apoptosis. Ad/Bax treatment was more effective in suppressing both subcutaneous and peritoneally disseminated MKN-45 tumours compared with Ad/p53 treatment. CONCLUSION Ad/Bax treatment significantly inhibited the growth of even p53 resistant gastric cancer in vitro and in vivo. Therefore, adenovirus mediated Bax gene transfer may be useful in gene therapy for gastric cancers.
Collapse
Affiliation(s)
- Y Tsunemitsu
- Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Yokoo K, Aoyama H, Tamada Y, Hashimoto T, Kuroyanagi Y, Kagawa S, Kubo K, Matsui H. 034
Application of Allogeneic Cultured Dermal Substitute to Skin Defects After Excision of Skin Cancer. Wound Repair Regen 2004. [DOI: 10.1111/j.1067-1927.2004.abstractaw.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
43
|
Tsunemitsu Y, Kagawa S, Tokunaga N, Otani S, Umeoka T, Tanaka N, Fujiwara T, Roth J, Fang B. 965 Molecular therapy for peritoneal dissemination of gastric cancer with adenovirus-mediated Bax gene transfer. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90992-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
44
|
Abstract
Plasmid DNA vectors (naked DNA) can easily be purified and transferred in vivo by intramuscular or intradermal injection. Naked DNA is stable in vivo, and long-term expression of the encoded protein is seen without chromosomal integration. Gene gun-mediated delivery of an expression plasmid is slightly more complicated but more efficient. These techniques have been applied to DNA vaccination or cytokine gene therapy for various diseases, including infections, autoimmune disorders, and cancer. We review cytokine gene therapy for cancer with naked DNA in animal models and present our preliminary data on gene gun-mediated in vivo transfection with the interleukin-12 gene in a murine renal cancer model. Because of its safety, simplicity, and low cost, cytokine gene therapy with naked DNA may become an important cancer treatment.
Collapse
Affiliation(s)
- M Nishitani
- Department of Urology, University of Tokushima School of Medicine, Tokushima, Japan.
| | | | | | | | | |
Collapse
|
45
|
Nakagawa K, Yamano S, Tsutsumi Y, Matsumoto M, Hinokio K, Irahara M, Aono T, Naroda T, Kagawa S. The scheduled ovarian hyperstimulation method makes it easy to perform ICSI with fresh testicular sperm (ICSI/TESE). Arch Androl 2002; 48:329-36. [PMID: 12230818 DOI: 10.1080/01485010290099165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The authors evaluated whether scheduled ovarian stimulation makes it easy to perform ICSI with fresh testicular sperm. Scheduled ovarian hyperstimulation was applied for testicular sperm extraction and ICSI with fresh testicular spermatozoa. Fifteen cycles in 10 couples were included in the present study; all couples were azoospermic, 5 were obstructive, and the remaining 5 were nonobstructive. No cycles were canceled, and all oocyte retrievals were performed on the scheduled day. Testicular sperm were obtained in 14 treatment cycles (93%). The mean numbers of retrieved and injected oocytes were 9.4 and 6.4, respectively. The fertilization and cleavage rates were 47 and 91%, respectively. Embryo transfers were performed in 12 cycles except 2 cycles that had no embryos. The number of transferred embryos was 2.3. Two clinical pregnancies were obtained. This scheduled ovarian hyperstimulation was applicable for ICSI with fresh testicular sperm.
Collapse
Affiliation(s)
- K Nakagawa
- Department of Obstetrics and Gynecology, School of Medicine, University of Tokushima, Tokushima, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Salama N, Tamura M, Tsuruo Y, Ishimura K, Kagawa S. Brain nitric oxides synthase in major pelvic ganglia of aged (LETO) and diabetic (OLETF) rats. Arch Androl 2002; 48:379-87. [PMID: 12230824 DOI: 10.1080/01485010290099291] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
This study was conducted to evaluate the effects of aging and diabetes mellitus (DM) on brain nitric oxide synthase (bNOS) expression in major pelvic ganglia (MPG) of rats. Otsuka Long Evans Tokushima Fatty rats (12, 30, and 70 weeks old), which are genetic models with non-insulin-dependent DM (NIDDM), and age-matched nondiabetic Long Evans Tokushima Otsuka controls were used. The MPG of all rats in this study were subjected to cryo-sectioning and staining with bNOS polyclonal AB and rhodamine-conjugated rabbit IgG. Fluorescence intensities of the stained neurons were assessed in randomly selected fields per each specimen. Animals of both groups revealed significant decline in the staining intensity of their neurons with aging and the progress of DM, but diabetic rats showed more decline than controls. In conclusion, both aging and NIDDM could decrease bNOS expression in rat MPG. However, NIDDM has a more evident effect than aging on that expression. The decrease in bNOS may cause a disturbance in functions of the target pelvic structures of these ganglia under both conditions.
Collapse
Affiliation(s)
- N Salama
- Department of Urology, School of Medicine, University of Tokushima, Tokushima City, Japan
| | | | | | | | | |
Collapse
|
47
|
Miyajima M, Matsuda M, Haga S, Kagawa S, Millar BC, Moore JE. Cloning and sequencing of 16S rDNA and 16S-23S rDNA internal spacer region (ISR) from urease-positive thermophilic Campylobacter (UPTC). Lett Appl Microbiol 2002; 34:287-9. [PMID: 11940161 DOI: 10.1046/j.1472-765x.2002.01082.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AIMS To clone and sequence the 16S rDNA and 16S-23S rDNA internal spacer region (ISR) from urease-positive thermophilic Campylobacter (UPTC). METHODS AND RESULTS The primer sets for 16S rDNA and 16S-23S rDNA ISR amplified almost the full length of 16S rDNA and 16S-23S rDNA ISR. About 1500 bp for 16S rDNA and about 720 bp for 16S-23S rDNA ISR of the rrn operon of four strains of UPTC were identified after molecular cloning and sequencing. CONCLUSIONS The four strains and CCUG18267 of UPTC showed approximately 99% sequence homology of 16S rDNA to each other, 96-97% to Camp. coli, 97-98% to Camp. jejuni and 97-98% to Camp. lari. SIGNIFICANCE AND IMPACT OF THE STUDY For the first time, the nucleotide sequence of 16S-23S rDNA ISR of UPTC has been analysed. The sequence of ISR was almost identical among the four strains of UPTC. It is interesting that the UPTC intercistronic tRNAs demonstrated an order of tRNA of 5'-16S-tRNAAla-tRNAIle-23S-3' in the organisms.
Collapse
Affiliation(s)
- M Miyajima
- Laboratory of Molecular Biology, School of Environmental Health Sciences, Azabu University, Fuchinobe, Japan
| | | | | | | | | | | |
Collapse
|
48
|
Matsuda M, Takayama K, Haga S, Kagawa S, Ohta H, Fukui K, Moore JE. Molecular genotyping of isolates of Actinobacillus actinomycetemcomitans by pulsed-field gel electrophoresis after separate digestion with Sse8387I and XhoI. J Basic Microbiol 2002; 42:137-44. [PMID: 11981879 DOI: 10.1002/1521-4028(200205)42:2<137::aid-jobm137>3.0.co;2-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Genomic DNA from 18 Japanese clinical isolates of Actinobacillus actinomycetemcomitans was obtained from six periodontitis patients and analyzed using pulsed-field gel electrophoresis (PFGE) after separate digestion with Sse8387I and with XhoI. Three isolates from an identical patient were found to share an identical PFGE profile, and isolates from distinct patients were found to have PFGE profiles distinctly different from each other. Consequently, the 18 Japanese clinical isolates were discriminated into six distinct genotypes by means of PFGE. The genomic DNA from the other six reference strains (ATCC33384, ATCC43717, ATCC 43718, JCM2434, JCM2435 and Nig-1) was discriminated into six genotypes by the same PFGE methodology, and these six genotypes were found to be distinctly different from the six genotypes of the 18 Japanese clinical isolates described above. Serotyping demonstrated three PFGE genotypes in the serotype a strains, four the serotype b strains and three the serotype c strains. The present results clearly suggest that the PFGE procedure after separate digestion with Sse8387I and with XhoI has an excellent discriminatory power amongst strains and has a good genotypability for A. actinomycetemcomitans.
Collapse
Affiliation(s)
- M Matsuda
- Laboratory of Molecular Biology, School of Environmental Health Sciences, Azabu University, Fuchinobe 1-17-71, Sagamihara 229-8501, UK.
| | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
BACKGROUND/AIMS Endogenous prostaglandins (PGs) are considered to play a pivotal role in maintaining the mucosal integrity of the stomach after injury. In the present study, we evaluated the mucosal ulcerogenic and mucosal blood flow (GMBF) responses in the stomach after damage by taurocholate (TC) in knockout mice lacking EP1 or EP3 receptors. METHODS Under urethane anaesthesia, a mouse stomach was mounted in an ex vivo chamber, exposed to 20 mmol/L TC for 20 min and treated with 20 mmol/L HCl before and after TC. GMBF was measured with a laser Doppler flowmeter. RESULTS Mucosal exposure to TC in wild-type mice caused a marked decrease in potential difference (PD), followed by an increase in H+ loss and GMBF. The decreased PD was gradually normalized after removal of TC from the chamber, with minimal damage in the mucosa 1 h after TC treatment. This hyperaemic response was inhibited by indomethacin, resulting in severe lesions in the mucosa without any change in PD or H+ loss. None of these responses induced by TC were altered in EP3-/- mice. However, in mice lacking EP1 receptors, TC treatment did not increase GMBF, despite causing PD reduction and acid loss, and resulted in severe damage in the mucosa. These responses were closely similar to those observed in animals pretreated with ONO-8711, a EP1 receptor antagonist. Mucosal PGE2 content was significantly increased after TC, similarly in all groups of mice. CONCLUSION These results confirm a mediator role for PGE2 in gastric hyperaemic response following mucosal exposure to TC and suggest that endogenous PGs may contribute to maintaining mucosal integrity after barrier disruption, mainly through activation of the EP1 receptor subtype.
Collapse
Affiliation(s)
- K Takeuchi
- Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Misasagi, Yamashina, Japan.
| | | | | | | |
Collapse
|
50
|
Murakami Y, Kanda K, Yokota K, Kanayama H, Kagawa S. Prognostic significance of immuno-proteosome subunit expression in patients with renal-cell carcinoma: a preliminary study. Mol Urol 2002; 5:113-9. [PMID: 11690558 DOI: 10.1089/10915360152559594] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Our purpose was to elucidate the clinical roles of the "immuno-proteosome," which is involved in the accelerated pathway of the major histocompatibility complex (MHC) class I-restricted antigen presentation system, in renal cell carcinoma (RCC). The relative expression of six proteosome subunits (existing subunits X, Y, and Z and immunoproteosome subunits LMP7, LMP2, and MECL1) in 54 RCCs was investigated using RT-PCR analysis and was compared with clinicopathological measures, including patient outcome. Expression of the LMP7 and LMP2 genes was significantly low in high-grade tumors, and that of the LMP7 and MECL1 genes was significantly low in high-stage tumors. Low levels of LMP7, LMP2, and MECL1 expression were strongly associated with shortened survival (LMP7: P = 0.0002, LMP2: P < 0.0001, MECL1: P < 0.0047). The levels of subunits X, Y, and Z had no significant correlation with those measures. These findings suggest that RCCs with low level of immuno-proteosome subunit expression have a disorder in their antigen-presentation system. As a consequence, they may escape from immune surveillance and worsen patient outcome.
Collapse
Affiliation(s)
- Y Murakami
- Department of Urology, School of Medicine, The University of Tokushima, Tokushima, Japan.
| | | | | | | | | |
Collapse
|